Synergy Pharmaceuticals (NASDAQ: SGYP) updated investors on the performance of its chronic idiopathic constipation (CIC) drug, Trulance, at the Ladenburg Thalmann Healthcare Conference on Sept. 26 and the Cantor Fitzgerald global healthcare conference on Sept. 27. Its message appears to have resonated with investors, since shares in Synergy Pharmaceuticals finished 12% higher on Friday.